BBLG
Bone Biologics Corp (BBLG, BBLGW
NASDAQ · Healthcare · Medical - Devices · US
$0.51
+2.42%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$0.52
From 52W high−81.65%
Volume107698.00
Market cap$1.41M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$0.52
From 52W high
−81.65%
Volume
107698.00
Market cap
$1.41M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
1.2x
P/E (TTM)
—
RSI (14)
26.0
MomentumView details →
1D Return
+2.42%
YTD Return
−64.40%
SummaryUpdated Jun 1, 2026
Bone Biologics Corporation (NASDAQ:BBLG) is a clinical-stage medical device company founded in 2004 and headquartered in Burlington, Massachusetts. The company went public in October 2021 and focuses on developing innovative bone regeneration solutions for spinal fusion procedures. Bone Biologics operates as a pre-revenue biotechnology company, dedicating its efforts to advancing a proprietary recombinant protein technology that aims to enhance bone healing outcomes in orthopedic surgery.
Similar companies
Latest newsMore news →
Bone Biologics Corp received a NASDAQ notice dated September 10, 2026 that it no longer complies with the minimum bid price requirement under Listing Rule 5550(a)(2), and intends to seek stockholder approval for a reverse stock split at its upcoming annual meeting.4d agoBone Biologics Corporation announced that six hospital sites in Australia have agreed to participate in its first-in-human pilot clinical trial of NB1, its rhNELL-1-based bone graft product for spinal fusion.12d ago